Ovid Therapeutics (OVID) Cash from Financing Activities (2016 - 2026)

Ovid Therapeutics (OVID) has reported Cash from Financing Activities for 11 consecutive years, with $21.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities changed N/A year-over-year to $21.6 million; the trailing twelve-month figure through Jun 2026 stood at $185.8 million (up 364168.63% YoY), and the FY2025 full-year result was $75.2 million, up 11991.16% from the prior year.
• Cash from Financing Activities eased to $21.6 million in Q2 2026 per OVID's latest filing, from $89.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $89.0 million in Q1 2026 and bottomed at -$43599.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $13.6 million across 5 years, with a median of $160274.5 in 2022.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities plunged 139.93% in 2022, then jumped 684376.92% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$43599.0 in 2022, then jumped by 68984.61% to $30.0 million in 2023, then plunged by 99.87% to $38000.0 in 2024, then surged by 197739.47% to $75.2 million in 2025, then plunged by 71.27% to $21.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $21.6 million, $89.0 million, and $75.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.